Covered versus bare-metal stenting of the mesenteric arteries in patients with chronic mesenteric ischaemia (CoBaGI) : a multicentre, patient-blinded and investigator-blinded, randomised controlled trial
Copyright © 2024 Elsevier Ltd. All rights reserved..
BACKGROUND: Mesenteric artery stenting with a bare-metal stent is the current treatment for atherosclerotic chronic mesenteric ischaemia. Long-term patency of bare-metal stents is unsatisfactory due to in-stent intimal hyperplasia. Use of covered stents might improve long-term patency. We aimed to compare the patency of covered stents and bare-metal stents in patients with chronic mesenteric ischaemia.
METHODS: We conducted a multicentre, patient-blinded and investigator-blinded, randomised controlled trial including patients with chronic mesenteric ischaemia undergoing mesenteric artery stenting. Six centres in the Netherlands participated in this study, including two national chronic mesenteric ischaemia expert centres. Patients aged 18 years or older were eligible for inclusion when an endovascular mesenteric artery revascularisation was scheduled and a consensus diagnosis of chronic mesenteric ischaemia was made by a multidisciplinary team of gastroenterologists, interventional radiologists, and vascular surgeons. Exclusion criteria were stenosis length of 25 mm or greater, stenosis caused by median arcuate ligament syndrome or vasculitis, contraindication for CT angiography, or previous target vessel revascularisation. Digital 1:1 block randomisation with block sizes of four or six and stratification by inclusion centre was used to allocate patients to undergo stenting with bare-metal stents or covered stents at the start of the procedure. Patients, physicians performing follow-up, investigators, and radiologists were masked to treatment allocation. Interventionalists performing the procedure were not masked. The primary study outcome was the primary patency of covered stents and bare-metal stents at 24 months of follow-up, evaluated in the modified intention-to-treat population, in which stents with missing data for the outcome were excluded. Loss of primary patency was defined as the performance of a re-intervention to preserve patency, or 75% or greater luminal surface area reduction of the target vessel. CT angiography was performed at 6 months, 12 months, and 24 months post intervention to assess patency. The study is registered with ClinicalTrials.gov (NCT02428582) and is complete.
FINDINGS: Between April 6, 2015, and March 11, 2019, 158 eligible patients underwent mesenteric artery stenting procedures, of whom 94 patients (with 128 stents) provided consent and were included in the study. 47 patients (62 stents) were assigned to the covered stents group (median age 69·0 years [IQR 63·0-76·5], 28 [60%] female) and 47 patients (66 stents) were assigned to the bare-metal stents group (median age 70·0 years [63·5-76·5], 33 [70%] female). At 24 months, the primary patency of covered stents (42 [81%] of 52 stents) was superior to that of bare-metal stents (26 [49%] of 53; odds ratio [OR] 4·4 [95% CI 1·8-10·5]; p<0·0001). A procedure-related adverse event occurred in 17 (36%) of 47 patients in the covered stents group versus nine (19%) of 47 in the bare-metal stent group (OR 2·4 [95% CI 0·9-6·3]; p=0·065). Most adverse events were related to the access site, including haematoma (five [11%] in the covered stents group vs six [13%] in the bare-metal stents group), pseudoaneurysm (five [11%] vs two [4%]), radial artery thrombosis (one [2%] vs none), and intravascular closure device (none vs one [2%]). Six (13%) patients in the covered stent group versus one (2%) in the bare-metal stent group had procedure-related adverse events not related to the access site, including stent luxation (three [6%] vs none), major bleeding (two (4%) vs none), mesenteric artery perforation (one [2%] vs one [2%]), mesenteric artery dissection (one [2%] vs one [2%]), and death (one [2%] vs none).
INTERPRETATION: The findings of this trial support the use of covered stents for mesenteric artery stenting in patients with chronic mesenteric ischaemia.
FUNDING: Atrium Maquet Getinge Group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
The lancet. Gastroenterology & hepatology - 9(2024), 4 vom: 15. März, Seite 299-309 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT02428582 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2468-1253(23)00402-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367910446 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367910446 | ||
| 003 | DE-627 | ||
| 005 | 20240311232213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2468-1253(23)00402-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM367910446 | ||
| 035 | |a (NLM)38301673 | ||
| 035 | |a (PII)S2468-1253(23)00402-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Terlouw, Luke G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Covered versus bare-metal stenting of the mesenteric arteries in patients with chronic mesenteric ischaemia (CoBaGI) |b a multicentre, patient-blinded and investigator-blinded, randomised controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02428582 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Mesenteric artery stenting with a bare-metal stent is the current treatment for atherosclerotic chronic mesenteric ischaemia. Long-term patency of bare-metal stents is unsatisfactory due to in-stent intimal hyperplasia. Use of covered stents might improve long-term patency. We aimed to compare the patency of covered stents and bare-metal stents in patients with chronic mesenteric ischaemia | ||
| 520 | |a METHODS: We conducted a multicentre, patient-blinded and investigator-blinded, randomised controlled trial including patients with chronic mesenteric ischaemia undergoing mesenteric artery stenting. Six centres in the Netherlands participated in this study, including two national chronic mesenteric ischaemia expert centres. Patients aged 18 years or older were eligible for inclusion when an endovascular mesenteric artery revascularisation was scheduled and a consensus diagnosis of chronic mesenteric ischaemia was made by a multidisciplinary team of gastroenterologists, interventional radiologists, and vascular surgeons. Exclusion criteria were stenosis length of 25 mm or greater, stenosis caused by median arcuate ligament syndrome or vasculitis, contraindication for CT angiography, or previous target vessel revascularisation. Digital 1:1 block randomisation with block sizes of four or six and stratification by inclusion centre was used to allocate patients to undergo stenting with bare-metal stents or covered stents at the start of the procedure. Patients, physicians performing follow-up, investigators, and radiologists were masked to treatment allocation. Interventionalists performing the procedure were not masked. The primary study outcome was the primary patency of covered stents and bare-metal stents at 24 months of follow-up, evaluated in the modified intention-to-treat population, in which stents with missing data for the outcome were excluded. Loss of primary patency was defined as the performance of a re-intervention to preserve patency, or 75% or greater luminal surface area reduction of the target vessel. CT angiography was performed at 6 months, 12 months, and 24 months post intervention to assess patency. The study is registered with ClinicalTrials.gov (NCT02428582) and is complete | ||
| 520 | |a FINDINGS: Between April 6, 2015, and March 11, 2019, 158 eligible patients underwent mesenteric artery stenting procedures, of whom 94 patients (with 128 stents) provided consent and were included in the study. 47 patients (62 stents) were assigned to the covered stents group (median age 69·0 years [IQR 63·0-76·5], 28 [60%] female) and 47 patients (66 stents) were assigned to the bare-metal stents group (median age 70·0 years [63·5-76·5], 33 [70%] female). At 24 months, the primary patency of covered stents (42 [81%] of 52 stents) was superior to that of bare-metal stents (26 [49%] of 53; odds ratio [OR] 4·4 [95% CI 1·8-10·5]; p<0·0001). A procedure-related adverse event occurred in 17 (36%) of 47 patients in the covered stents group versus nine (19%) of 47 in the bare-metal stent group (OR 2·4 [95% CI 0·9-6·3]; p=0·065). Most adverse events were related to the access site, including haematoma (five [11%] in the covered stents group vs six [13%] in the bare-metal stents group), pseudoaneurysm (five [11%] vs two [4%]), radial artery thrombosis (one [2%] vs none), and intravascular closure device (none vs one [2%]). Six (13%) patients in the covered stent group versus one (2%) in the bare-metal stent group had procedure-related adverse events not related to the access site, including stent luxation (three [6%] vs none), major bleeding (two (4%) vs none), mesenteric artery perforation (one [2%] vs one [2%]), mesenteric artery dissection (one [2%] vs one [2%]), and death (one [2%] vs none) | ||
| 520 | |a INTERPRETATION: The findings of this trial support the use of covered stents for mesenteric artery stenting in patients with chronic mesenteric ischaemia | ||
| 520 | |a FUNDING: Atrium Maquet Getinge Group | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a van Dijk, Louisa J D |e verfasserin |4 aut | |
| 700 | 1 | |a van Noord, Desirée |e verfasserin |4 aut | |
| 700 | 1 | |a Bakker, Olaf J |e verfasserin |4 aut | |
| 700 | 1 | |a Bijdevaate, Diederik C |e verfasserin |4 aut | |
| 700 | 1 | |a Erler, Nicole S |e verfasserin |4 aut | |
| 700 | 1 | |a Fioole, Bram |e verfasserin |4 aut | |
| 700 | 1 | |a Harki, Jihan |e verfasserin |4 aut | |
| 700 | 1 | |a van den Heuvel, Daniel A F |e verfasserin |4 aut | |
| 700 | 1 | |a Hinnen, Jan Willem |e verfasserin |4 aut | |
| 700 | 1 | |a Kolkman, Jeroen J |e verfasserin |4 aut | |
| 700 | 1 | |a Nikkessen, Suzan |e verfasserin |4 aut | |
| 700 | 1 | |a van Petersen, André S |e verfasserin |4 aut | |
| 700 | 1 | |a Smits, Henk F M |e verfasserin |4 aut | |
| 700 | 1 | |a Verhagen, Hence J M |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Annemarie C |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Jean-Paul P M |e verfasserin |4 aut | |
| 700 | 1 | |a Vroegindeweij, Dammis |e verfasserin |4 aut | |
| 700 | 1 | |a Geelkerken, Robert H |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Marco J |e verfasserin |4 aut | |
| 700 | 1 | |a Moelker, Adriaan |e verfasserin |4 aut | |
| 700 | 0 | |a Dutch Mesenteric Ischemia Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Balm, Ron |e investigator |4 oth | |
| 700 | 1 | |a Bakker, Olaf J |e investigator |4 oth | |
| 700 | 1 | |a Bijdevaate, Diederik C |e investigator |4 oth | |
| 700 | 1 | |a Blauw, Juliette T |e investigator |4 oth | |
| 700 | 1 | |a de Borst, Gert Jan |e investigator |4 oth | |
| 700 | 1 | |a Bos, Philip R |e investigator |4 oth | |
| 700 | 1 | |a Bruno, Marco J |e investigator |4 oth | |
| 700 | 1 | |a Buscher, Hessel C J L |e investigator |4 oth | |
| 700 | 1 | |a van Dijk, Louisa J D |e investigator |4 oth | |
| 700 | 1 | |a van Duivenvoorden, Annet A M |e investigator |4 oth | |
| 700 | 1 | |a Erler, Nicole S |e investigator |4 oth | |
| 700 | 1 | |a Fioole, Bram |e investigator |4 oth | |
| 700 | 1 | |a Geelkerken, Robert H |e investigator |4 oth | |
| 700 | 1 | |a Hamming, Jaap F |e investigator |4 oth | |
| 700 | 1 | |a Harki, Jihan |e investigator |4 oth | |
| 700 | 1 | |a Harmankaya, Duygu |e investigator |4 oth | |
| 700 | 1 | |a van Hattum, Eline S |e investigator |4 oth | |
| 700 | 1 | |a van den Heuvel, Daniel A F |e investigator |4 oth | |
| 700 | 1 | |a Hinnen, Jan Willem |e investigator |4 oth | |
| 700 | 1 | |a Kolkman, Jeroen J |e investigator |4 oth | |
| 700 | 1 | |a van der Laan, Maarten J |e investigator |4 oth | |
| 700 | 1 | |a Lenaerts, Kaatje |e investigator |4 oth | |
| 700 | 1 | |a Lubbers, Tim |e investigator |4 oth | |
| 700 | 1 | |a van der Lugt, Mark |e investigator |4 oth | |
| 700 | 1 | |a Metz, Floor M |e investigator |4 oth | |
| 700 | 1 | |a Moelker, Adriaan |e investigator |4 oth | |
| 700 | 1 | |a Nikkessen, Suzan |e investigator |4 oth | |
| 700 | 1 | |a van Noord, Derirée |e investigator |4 oth | |
| 700 | 1 | |a Parikh, Kaushal |e investigator |4 oth | |
| 700 | 1 | |a van der Schaar, Peter J |e investigator |4 oth | |
| 700 | 1 | |a Smits, Henk F M |e investigator |4 oth | |
| 700 | 1 | |a Terlouw, Luke G |e investigator |4 oth | |
| 700 | 1 | |a Verhagen, Hence J M |e investigator |4 oth | |
| 700 | 1 | |a de Vries, Annemarie C |e investigator |4 oth | |
| 700 | 1 | |a de Vries, Jean Paul P M |e investigator |4 oth | |
| 700 | 1 | |a Vroegindeweij, Dammis |e investigator |4 oth | |
| 700 | 1 | |a Welten, Gijs M J M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Gastroenterology & hepatology |d 2016 |g 9(2024), 4 vom: 15. März, Seite 299-309 |w (DE-627)NLM264051246 |x 2468-1253 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:4 |g day:15 |g month:03 |g pages:299-309 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2468-1253(23)00402-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 4 |b 15 |c 03 |h 299-309 | ||